| Autor: |
Andersson K; Department of Laboratory Medicine, Unit of Clinical Microbiology, Karolinska Institutet, 17177 Stockholm, Sweden.; Biomedrex Genetics, Alfred Nobels allé 8, 14152 Stockholm, Sweden., Azatyan A; Biomedrex Genetics, Alfred Nobels allé 8, 14152 Stockholm, Sweden., Ekenberg M; Biomedrex Genetics, Alfred Nobels allé 8, 14152 Stockholm, Sweden., Güçlüler G; Biomedrex Genetics, Alfred Nobels allé 8, 14152 Stockholm, Sweden., Sardon Puig L; Biomedrex Genetics, Alfred Nobels allé 8, 14152 Stockholm, Sweden., Puumalainen M; Biomedrex Genetics, Alfred Nobels allé 8, 14152 Stockholm, Sweden., Pramer T; Biomedrex Genetics, Alfred Nobels allé 8, 14152 Stockholm, Sweden., Monteil VM; Department of Laboratory Medicine, Unit of Clinical Microbiology, Karolinska Institutet, 17177 Stockholm, Sweden.; Public Health Agency of Sweden, 17182 Solna, Sweden., Mirazimi A; Department of Laboratory Medicine, Unit of Clinical Microbiology, Karolinska Institutet, 17177 Stockholm, Sweden.; Public Health Agency of Sweden, 17182 Solna, Sweden.; National Veterinary Institute, 75189 Uppsala, Sweden. |
| Abstrakt: |
In a time of climate change, population growth, and globalization, the risk of viral spread has significantly increased. The 21st century has already witnessed outbreaks of Severe Acute Respiratory Syndrome virus (SARS-CoV), Severe Acute Respiratory Syndrome virus 2 (SARS-CoV-2), Ebola virus and Influenza virus, among others. Viruses rapidly adapt and evade human immune systems, complicating the development of effective antiviral countermeasures. Consequently, the need for novel antivirals resilient to viral mutations is urgent. In this study, we developed a CRISPR-Cas13b system to target SARS-CoV-2. Interestingly, this system was also efficient against SARS-CoV, demonstrating broad-spectrum potential. Our findings highlight CRISPR-Cas13b as a promising tool for antiviral therapeutics, underscoring its potential in RNA-virus-associated pandemic responses. |
